{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:23:32Z","timestamp":1777598612198,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12029-020-00392-1","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T05:32:01Z","timestamp":1584077521000},"page":"237-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Angiopoietin-2 as a Prognostic Factor in Patients with Incurable Stage IV Colorectal Cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Shinya","family":"Munakata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takae","family":"Ueyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Tomiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"392_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"392_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrc2894","volume":"10","author":"H Huang","year":"2010","unstructured":"Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575\u201385.","journal-title":"Nat Rev Cancer"},{"key":"392_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1126\/science.277.5322.55","volume":"277","author":"PC Maisonpierre","year":"1997","unstructured":"Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55\u201360.","journal-title":"Science"},{"key":"392_CR4","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/1097-0142(20010901)92:5<1138::AID-CNCR1431>3.0.CO;2-L","volume":"92","author":"SA Ahmad","year":"2001","unstructured":"Ahmad SA, Liu W, Jung YD, et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma A possible mechanism for the initiation of angiogenesis. Cancer. 2001;92:1138\u201343.","journal-title":"Cancer"},{"key":"392_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1684\/ecn.2012.0308","volume":"23","author":"H Engin","year":"2012","unstructured":"Engin H, Ustundag Y, Tekin IO, Gokmen A, Ertop S, Ilikhan SU. Plasma concentrations of angiopoietin-1, angiopoietin-2 and Tie-2 in colon cancer. Eur Cytokine Netw. 2012;23:68\u201371.","journal-title":"Eur Cytokine Netw"},{"key":"392_CR6","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471\u20134.","journal-title":"Ann Surg Oncol"},{"key":"392_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.6004\/jnccn.2013.0022","volume":"11","author":"AB Benson 3rd","year":"2013","unstructured":"Benson AB 3rd, Bekaii-Saab T, Chan E, et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013;11:141\u201352.","journal-title":"J Natl Compr Cancer Netw"},{"key":"392_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1186\/1471-2407-14-696","volume":"14","author":"H Sallinen","year":"2014","unstructured":"Sallinen H, Heikura T, Koponen J, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer. 2014;14:696.","journal-title":"BMC Cancer"},{"key":"392_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/sj.bjc.6605925","volume":"103","author":"V Goede","year":"2010","unstructured":"Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010;103:1407\u201314.","journal-title":"Br J Cancer"},{"key":"392_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/SLA.0b013e318238346a","volume":"255","author":"GE van der Wal","year":"2012","unstructured":"van der Wal GE, Gouw AS, Kamps JA, Moorlag HE, Bulthuis ML, Molema G, et al. Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg. 2012;255:86\u201394.","journal-title":"Ann Surg"},{"key":"392_CR11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/1097-0142(20010901)92:5<1138::AID-CNCR1431>3.0.CO;2-L","volume":"92","author":"SA Ahmad","year":"2001","unstructured":"Ahmad SA, Liu WB, Jung YD, Fan F, Reinmuth N, Bucana CD, et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma\u2014a possible mechanism for the initiation of angiogenesis. Cancer. 2001;92:1138\u201343.","journal-title":"Cancer"},{"key":"392_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.yexcr.2005.09.002","volume":"312","author":"L Eklund","year":"2006","unstructured":"Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res. 2006;312:630\u201341.","journal-title":"Exp Cell Res"},{"key":"392_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3393\/ac.2017.33.1.9","volume":"33","author":"S Hong","year":"2017","unstructured":"Hong S, Jung HI, Ahn TS, Kim HJ, Lee KT, Baek MJ, et al. Expressions and clinical significances of angiopoietin-1, angiopoietin-2, and Tie-2 receptor in patients with colorectal cancer. Ann Coloproctol. 2017;33:9\u201315.","journal-title":"Ann Coloproctol"},{"key":"392_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00109-002-0397-4","volume":"81","author":"H-P Gerber","year":"2002","unstructured":"Gerber H-P, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med. 2002;81:20\u201331.","journal-title":"J Mol Med"},{"key":"392_CR15","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013\u20139.","journal-title":"J Clin Oncol"},{"key":"392_CR16","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-09-1977","volume":"70","author":"H Hashizume","year":"2010","unstructured":"Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010;70:2213\u201323.","journal-title":"Cancer Res"},{"key":"392_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fphar.2017.00193","volume":"8","author":"KA Bohn","year":"2017","unstructured":"Bohn KA, Adkins CE, Nounou MI, Lockman PR. Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Front Pharmacol. 2017;8:193.","journal-title":"Front Pharmacol"},{"key":"392_CR18","doi-asserted-by":"crossref","unstructured":"Isambert N, Elez E, Zanetta S, Matos I, Nazabadioko S, Xue WQ (2018) A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)\/angiopoietin-2 (Ang-2)-blocking nanobody, in patients (pts) with advanced\/metastatic solid tumors. J Clin Oncol 36.","DOI":"10.1200\/JCO.2018.36.15_suppl.e24013"},{"key":"392_CR19","doi-asserted-by":"publisher","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9:eaak9670.","journal-title":"Sci Transl Med"},{"key":"392_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/2326-6066.CIR-16-0206","volume":"5","author":"X Wu","year":"2017","unstructured":"Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, et al. Angiopoietin-2 as a biomarker and target for immune checkpoint therapy. Cancer Immunol Res. 2017;5:17\u201328.","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-020-00392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-020-00392-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-020-00392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:09:44Z","timestamp":1628600984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-020-00392-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1007\/s12029-020-00392-1","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"13 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the ethical standards of the Committee on Human Experimentation of our institution. All procedures were followed in accordance with the current revision of Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}